Xing Liu

Dr. Xing Liu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JHJun Jacob Hu
Jun Jacob Hu
XLXing Liu
Xing Liu
SXShiyu Xia
Shiyu Xia
ZZZhibin Zhang
Zhibin Zhang
YZYing Zhang
Ying Zhang
HWHao Wu
Hao Wu

10 March 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
XLXing Liu
Xing Liu
SXShiyu Xia
Shiyu Xia
ZZZhibin Zhang
Zhibin Zhang
HWHao Wu
Hao Wu
JLJudy Lieberman
Judy Lieberman

3 November 2023 in Immunity
Verified
Journal Article
Closed access
RMRui Miao
Rui Miao
CJCong Jiang
Cong Jiang
WCWinston Y. Chang
Winston Y. Chang
HZHaiwei Zhang
Haiwei Zhang
JAJinsu An
Jinsu An
JLJudy Lieberman
Judy Lieberman

2 February 2022 in Nature
Verified
Journal Article
Closed access
PDF file
WDWanyan Deng
Wanyan Deng
YBYang Bai
Yang Bai
FDFan Deng
Fan Deng
YPYoudong Pan
Youdong Pan
SMShenglin Mei
Shenglin Mei
XLXing Liu
Xing Liu

7 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ZHZe Hong
Ze Hong
JMJiahao Mei
Jiahao Mei
CLChenhui Li
Chenhui Li
GBGuohui Bai
Guohui Bai
MMMunire Maimaiti
Munire Maimaiti
CWChen Wang
Chen Wang
Cytosolic DNA activates cGAS (cytosolic DNA sensor cyclic AMP-GMP synthase)-STING (stimulator of interferon genes) signaling, which triggers interferon and inflammatory responses that help defend against microbial infection and cancer. However, aberrant cytosolic self-DNA in Aicardi–Goutière’s syndrome and constituently active gain-of-function mutations in STING in STING-associated vasculopathy with onset in infancy (SAVI) patients lead to excessive type I interferons and proinflammatory cytokines, which cause difficult-to-treat and sometimes fatal autoimmune disease. Here, in silico docking identified a potent STING antagonist SN-011 that binds with higher affinity to the cyclic dinucleotide (CDN)-binding pocket of STING than endogenous 2′3′-cGAMP. SN-011 locks STING in an open inactive conformation, which inhibits interferon and inflammatory cytokine induction activated by 2′3′-cGAMP, herpes simplex virus type 1 infection, Trex1 deficiency, overexpression of cGAS-STING, or SAVI STING mutants. In Trex1−/− mice, SN-011 was well tolerated, strongly inhibited hallmarks of inflammation and autoimmunity disease, and prevented death. Thus, a specific STING inhibitor that binds to the STING CDN-binding pocket is a promising lead compound for STING-driven disease. Significance cGAS (cytosolic DNA sensor cyclic AMP-GMP synthase)-STING (stimulator of interferon genes) signaling is critical for sensing cytosolic DNA to initiate host immune responses against invading pathogens and cancer. However, inappropriate activation of STING signaling causes severe and often fatal autoimmune or autoinflammatory diseases. Hence, STING is an attractive drug target for the treatment of STING-driven autoimmune and inflammatory disorders. Therefore, there is a need to identify lead compounds that effectively inhibit human STING for further drug development. Here, we identified and characterized a STING-specific inhibitor SN-011 with high efficiency, specificity, and safety, paving the way for therapeutically manipulating STING-mediated clinical diseases.

1 December 2018 in Cell Reports
Verified
Journal Article
Open access
SLSenlin Li
Senlin Li
ZHZe Hong
Ze Hong
ZWZhe Wang
Zhe Wang
FLFei Li
Fei Li
JMJiahao Mei
Jiahao Mei
CWChen Wang
Chen Wang
CGAS-STING signaling is essential for innate immunity. Its misregulation promotes cancer or autoimmune and autoinflammatory diseases, and it is imperative to identify effective lead compounds that specifically downregulate the pathway. We report here that astin C, a cyclopeptide isolated from the medicinal plant Aster tataricus, inhibits cGAS-STING signaling and the innate inflammatory responses triggered by cytosolic DNAs. Moreover, mice treated with astin C are more susceptible to HSV-1 infection. Consistently, astin C markedly attenuates the autoinflammatory responses in Trex1-/- BMDM cells and in Trex1-/- mouse autoimmune disease model. Mechanistically, astin C specifically blocks the recruitment of IRF3 onto the STING signalosome. Collectively, this study characterizes a STING-specific small-molecular inhibitor that may be applied for potentially manipulating the STING-mediated clinical diseases.